Bonesupport Holding (BONEX) Stock Overview
An orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BONEX Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 253.20 |
| 52 Week High | SEK 405.80 |
| 52 Week Low | SEK 240.80 |
| Beta | 0.66 |
| 1 Month Change | -11.22% |
| 3 Month Change | -22.80% |
| 1 Year Change | 0.48% |
| 3 Year Change | 289.24% |
| 5 Year Change | 523.65% |
| Change since IPO | 691.25% |
Recent News & Updates
Recent updates
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
Apr 28
CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence
CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results
Mar 01Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
Oct 31We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth
Mar 16Shareholder Returns
| BONEX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.7% | -5.7% | -2.9% |
| 1Y | 0.5% | -7.1% | -4.2% |
Return vs Industry: BONEX exceeded the Swedish Biotechs industry which returned -7.1% over the past year.
Return vs Market: BONEX exceeded the Swedish Market which returned -4.2% over the past year.
Price Volatility
| BONEX volatility | |
|---|---|
| BONEX Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 4.0% |
Stable Share Price: BONEX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BONEX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 140 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| BONEX fundamental statistics | |
|---|---|
| Market cap | SEK 16.68b |
| Earnings (TTM) | SEK 122.34m |
| Revenue (TTM) | SEK 997.85m |
Is BONEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONEX income statement (TTM) | |
|---|---|
| Revenue | SEK 997.85m |
| Cost of Revenue | SEK 73.86m |
| Gross Profit | SEK 923.99m |
| Other Expenses | SEK 801.66m |
| Earnings | SEK 122.34m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 15, 2025
| Earnings per share (EPS) | 1.86 |
| Gross Margin | 92.60% |
| Net Profit Margin | 12.26% |
| Debt/Equity Ratio | 0% |
How did BONEX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/15 08:15 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bonesupport Holding AB (publ) is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Jonas Peciulis | Edison Investment Research |